Biological influence of Hakai in cancer: a 10-year review
Luís Antón Aparicio(Universidade da Coruña), Angélica Figueroa(Universidade da Coruña), M. Blanco(Hospital Universitari de Girona Doctor Josep Trueta), Guillermo Alonso(Hospital Italiano de Buenos Aires), Manuel Valladares(American Society of Clinical Oncology)
Cited by 47
Related Papers
Cancer drug resistance induced by EMT: novel therapeutic strategies
|Archives of Toxicology|2021|220
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
|The Oncologist|2012|213
The clinical–DWI mismatch
|Neurology|2004|207
Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy
|International Journal of Endocrinology|2010|175